ACE Inhibitors Market Forecasted to Surge to $9 Billion by 2028 Amid Growing Cardiovascular and Hypertension Concerns


Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "ACE Inhibitors Global Market Report 2024" has been added to ResearchAndMarkets.com's offering.

The global ACE inhibitors market is projected to experience robust growth, reaching a market value of $9 billion by 2028, with a notable CAGR of 5.6%. This expansion is underpinned by the escalating prevalence of cardio-renal diseases such as hypertension, which requires effective treatment options like ACE inhibitors.

The market has seen sustainable growth from $6.9 billion in 2023 and is poised to incrementally rise to $7.24 billion in 2024. This upward trajectory can be attributed to the increasing incidence of cardiovascular diseases globally, a burgeoning aging population susceptible to chronic health conditions, and regulatory endorsements enhancing the visibility and trust in ACE inhibitors for managing several health conditions including diabetes.

Escalating Burden of Hypertension

A significant growth driver for the ACE inhibitor products is the rising global burden of hypertension. According to the World Health Organization, over a billion individuals are affected by hypertension, with a significant percentage unaware of their condition. ACE inhibitors are critical in the management of elevated blood pressure levels, offering therapeutic benefits in vascular relaxation and blood flow improvement.

Cardiovascular Disorders Fueling Demand

Furthermore, the rising incidence of cardiac disorders such as heart failure and coronary artery disease catalyzes the demand for ACE inhibitors. These medications are integral to managing such disorders by reducing vasoconstriction and improving heart function.

Market Trends and Innovations

  • Focus on Renal Protection: Increased emphasis on preserving kidney function in patients with hypertension and diabetes.
  • Combination Therapies: Advances in combination therapy formulations to enhance patient adherence and therapeutic outcomes.
  • Generics and Competition: The proliferation of generic medications fostering accessibility but also bringing pricing pressures.
  • Patient-Centric Care: A shift towards personalized healthcare approaches to maximize treatment efficacy.
  • Regulatory and Safety Considerations: Ongoing updates in regulatory guidelines to ensure the safety and effectiveness of ACE inhibitors.

Regional Insights

North America remains the predominant region in the ACE inhibitors market, bolstered by comprehensive healthcare infrastructure and awareness programs. Asia-Pacific is poised to emerge as the fastest-growing region, underlining the increased healthcare access and rising prevalence of lifestyle diseases in the region.

Noteworthy players in the ACE inhibitors space, such as Pfizer Inc., Novartis AG, and Johnson & Johnson, continue to innovate and develop efficacious drugs to meet the growing demand for treatments in this therapeutic area.

This latest study on the ACE inhibitors market provides an in-depth analysis of market trends, growth drivers, and the competitive landscape, shedding light on the key factors influencing the industry's trajectory towards 2028. The comprehensive report serves as a valuable resource for stakeholders within the healthcare sector, policymakers, and investors monitoring the pharmaceutical landscape for heart health and blood pressure management solutions.

As the ACE inhibitors market continues its growth path, this report's findings are a testament to the sustained investment and focus in cardiovascular and kidney health arenas, highlighting advancements, challenges, and opportunities within this dynamic healthcare segment.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
  • The impact of higher inflation in many countries and the resulting spike in interest rates.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Companies Profiled:

  • Pfizer Inc.
  • Novartis AG
  • Johnson & Johnson Private Limited
  • Merck KGaA
  • Sanofi S.A.
  • Bayer AG
  • United Therapeutics Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Co.
  • Takeda Pharmaceuticals Company
  • Daiichi Sankyo Company Ltd.
  • UCB Schwarz Pharma Inc.
  • Solvay Pharmaceuticals B.V.
  • Endo International plc
  • Otto Brandes GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim
  • Bausch Health Companies Inc.
  • Dr. Reddy's Laboratories
  • Abbott Laboratories
  • Eli Lilly and Company
  • Cipla Limited
  • GlaxoSmithKline plc
  • Cadila Healthcare Limited
  • AbbVie Inc.
  • Mylan N.V.
  • Sandoz Group AG
  • Accord Healthcare Ltd.
  • AstraZeneca plc
  • Lupin Limited
  • Macleods Pharmaceuticals Limited
  • Zydus lifescience Ltd.
  • Apotex Inc.



For more information about this report visit https://www.researchandmarkets.com/r/srrvew

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

 

Contact Data